Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Cell. 2012 Dec 11;22(6):812-24. doi: 10.1016/j.ccr.2012.11.003.

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.

Author information

1
Division of Hematology and Medical Oncology, Weill Cornell Medical College, New York, NY 10021, USA.

Abstract

MALT1 cleavage activity is linked to the pathogenesis of activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), a chemoresistant form of DLBCL. We developed a MALT1 activity assay and identified chemically diverse MALT1 inhibitors. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. MI-2 concentrated within human ABC-DLBCL cells and irreversibly inhibited cleavage of MALT1 substrates. This was accompanied by NF-κB reporter activity suppression, c-REL nuclear localization inhibition, and NF-κB target gene downregulation. Most notably, MI-2 was nontoxic to mice, and displayed selective activity against ABC-DLBCL cell lines in vitro and xenotransplanted ABC-DLBCL tumors in vivo. The compound was also effective against primary human non-germinal center B cell-like DLBCLs ex vivo.

Comment in

PMID:
23238016
PMCID:
PMC3984478
DOI:
10.1016/j.ccr.2012.11.003
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center